文献速递骨软组织肉瘤与黑色素瘤

Tebentafusp治疗转移性葡萄膜黑色素瘤的五年生存分析

Five-year survival with tebentafusp in metastatic uveal melanoma.
PubMed 文献 · Ann Oncol · 2026-05-19

这项国际开放标签3期试验纳入既往未治疗的HLA-A*02:01阳性转移性葡萄膜黑色素瘤患者,按2:1随机接受tebentafusp或研究者选择的帕博利珠单抗、伊匹木单抗或达卡巴嗪。中位随访至少5年后,tebentafusp组中位总生存21.6个月,对照组16.9个月,分层风险比0.67(95%CI 0.54-0.85),5年总生存率分别为16%与8%。

要点

  • tebentafusp较研究者选择显著改善既往未治疗HLA-A*02:01阳性mUM的总生存。
  • 5年总生存率为16%对8%,中位总生存为21.6个月对16.9个月。
  • 基线ctDNA可测或第9周ctDNA下降≥50%与tebentafusp组更长生存相关。

核心结论

  • 在mUM随机试验中最长的生存随访中,tebentafusp对既往未治疗的HLA-A*02:01阳性患者持续提供长期生存获益。

研究设计与样本

  • 国际、开放标签、3期试验,既往未治疗的HLA-A*02:01阳性mUM患者按2:1随机接受tebentafusp或研究者选择的帕博利珠单抗、伊匹木单抗或达卡巴嗪,按乳酸脱氢酶分层。
  • 主要终点为总生存,循环肿瘤DNA(ctDNA)下降为探索性终点。

主要发现

  • 至少5年随访后,tebentafusp组中位总生存21.6个月,对照组16.9个月,分层风险比0.67(95%CI 0.54-0.85)。
  • 5年总生存率tebentafusp组16%,对照组8%。
  • tebentafusp在预后不良组(如基线肿瘤≥10 cm或最佳RECISTv1.1疗效为疾病进展,包括靶病灶增长超过20%)也改善生存。
  • 事后分析显示,调整协变量后,影像学进展后继续tebentafusp治疗的患者总生存长于停药者。
  • tebentafusp组中,基线ctDNA不可测或第9周ctDNA下降≥50%与更长总生存相关;深度ctDNA下降与基线肿瘤负荷或影像学疗效无关。

临床怎么用

  • tebentafusp可作为既往未治疗HLA-A*02:01阳性mUM患者的一线标准治疗。
  • 治疗中影像学进展后继续tebentafusp可能带来生存获益。
  • 基线及第9周ctDNA动态可用于评估tebentafusp治疗后的生存预后。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tebentafusp demonstrated an overall survival benefit compared with investigator's choice in a phase 3 trial in HLA-A∗02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM) and is now the first-line standard of care for this population. In this study, we report the final 5-year analysis of overall survival. PATIENTS AND METHODS: In this international, open-label, phase 3 trial, previously untreated HLA-A∗02:01-positive patients with mUM were randomized 2:1 to receive tebentafusp or investigator's choice of pembrolizumab, ipilimumab, or dacarbazine (control group), stratified by lactate dehydrogenase. The primary endpoint was overall survival; circulating tumor DNA (ctDNA) reduction was an exploratory endpoint. RESULTS: After a minimum of 5 years of follow-up, median overall survival was 21.6 months in the tebentafusp group and 16.9 months in the control group (stratified hazard ratio 0.67, 95% confidence interval 0.54-0.85). Overall survival at 5 years was 16% versus 8%, respectively. Tebentafusp improved survival even in poor-prognosis groups, such as patients with baseline tumors ≥10 cm or those whose best RECISTv1.1 response was progressive disease, including cases where target tumor growth exceeded 20%. After adjusting for covariates, a post hoc analysis showed that patients who were treated with tebentafusp beyond radiographic progression had longer overall survival than those who discontinued treatment. In the tebentafusp group, longer overall survival was associated with undetectable ctDNA at baseline or ctDNA reductions ≥50% by week 9. Deep ctDNA reductions occurred regardless of baseline tumor burden or radiographic response. CONCLUSIONS: In the longest survival follow-up of a randomized trial in mUM, tebentafusp continues to provide long-term survival benefit in previously untreated HLA-A∗02:01-positive patients. GOV IDENTIFIER: NCT03070392.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Piperno-Neumann S, Rutkowski P, Hassel JC, et al. Five-year survival with tebentafusp in metastatic uveal melanoma. Ann Oncol. 2026. PMID: 42162665. doi:10.1016/j.annonc.2026.05.695

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。